Apellis Presents 24-Month P-III (OAKS) Post Hoc Results of Pegcetacoplan for the Treatment of Geographic Atrophy at AAO 2022
Shots:
- The P-III (OAKS) study evaluated pegcetacoplan (IVI) vs sham in 637 patients with GA. The post hoc analyses of microperimetry data showed a reduction of retinal sensitivity in monthly & EOM with increasing effects over time, slowing GA lesion growth will preserve visual function & patients had fewer new scotomatous points @24mos. & had a favorable safety profile
- The rates of infectious endophthalmitis & intraocular inflammation were consistent with reported rates in studies of other IVI therapies & the combined rate of new-onset exudations in monthly, EOM & sham groups (12.2%, 6.7% & 3.1%), respectively
- The company plans to submit the MAA to the EMA at the end of 2022. The US marketing application is under Priority Review with an accepted PDUFA date of Nov 2022
Ref: Globenewswire | Image: Apellis
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
